Adding a gonadotropin-releasing hormone analog to cyclophosphamide-containing chemotherapy significantly reduces the risk for premature ovarian insufficiency in premenopausal women with breast cancer, Chinese research shows.

Aromatase inhibitors significantly reduce the risk for breast cancer recurrence relative to tamoxifen in premenopausal women treated with ovarian function suppression, suggests a patient-level meta-analysis.

Based on the available data on ovarian cancer during pregnancy, we performed a review and meta-analysis to evaluate the efficacy and safety of platinum-based chemotherapy against ovarian cancer during pregnancy.

SOLO1 co-author Susana Banerjee provides a quick take on the study findings and discusses the challenges going forward (3:55).

Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.

The risk for death from ovarian cancer is around a third lower among women who regularly use aspirin or other nonsteroidal anti-inflammatory drugs after diagnosis, compared with nonusers, US study data show.

Progression-free survival is significantly improved with the use of maintenance olaparib in women with newly diagnosed FIGO stage III or IV ovarian cancer and a BRCA1 / 2 mutation, shows the placebo-controlled SOLO1 trial.

Women using contemporary combined oral contraceptives containing newer progestogens have a reduced risk for ovarian cancer compared with women not using hormonal contraception, a nationwide cohort study shows.

Adding ovarian suppression to tamoxifen significantly improves disease-free survival over tamoxifen alone in premenopausal women with hormone receptor-positive breast cancer, the latest data from the SOFT and TEXT trials show.

medwireNews : The EMA has adopted a positive opinion for use of the PARP inhibitor rucaparib in patients with progressive or relapsed ovarian cancer.

By Lynda Williams medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group See also: Rucaparib authorization recommended for relapsed, progressive ovarian cancer ARIEL3 demonstrates maintenance rucaparib benefit for advanced platinum-sensitive ovarian cancer

Women with advanced-stage ovarian cancer derive a significant survival benefit from the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery, phase III trial results indicate. Read the linked commentary from Krishnansu Tewari

Beesley VL et al. Support Care Cancer 2018; 26: 4133. doi:10.1007/s00520-018-4284-0

Individuals with high-grade serous ovarian cancer are more than twice as likely as those without cancer to have white blood cell BRCA1 promoter methylation, study findings indicate.

Temporary ovarian suppression with a gonadotropin-releasing hormone analog alongside neoadjuvant or adjuvant chemotherapy could help preserve ovarian function and fertility in premenopausal women with early-stage breast cancer, shows a pooled analysis.

Patients with platinum-resistant ovarian cancer gain significant survival benefit from treatment with bevacizumab, regardless of whether its given with or after chemotherapy, an exploratory analysis of AURELIA study data show.